

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Task Force



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Aboyans Victor	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Hyperlipidemia (2015) - Novartis : Hypertension (2015-2016) - Boehringer-Ingelheim : Oral anticoagulation (2015-2016) - Bayer Healthcare : Oral anticoagulation (2015-2016) - Pfizer/BMS alliance : Oral anticoagulation (2015-2016) - Amgen : Hyperlipidemia (2016)
Bartelink Mel	Nothing to be declared (2015-2016)
Bjorck Martin	Nothing to be declared (2016) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astrazeneca : Ticagrelor, platelet inhibitor (2015)
Brodmann Marianne	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : anticoagulants (2015) - Boehringer-Ingelheim : oral anticoagulants (2015) - Daiichi Sankyo : oral anticoagulants (2015) - Bayer Healthcare : oral anticoagulants (2015) - Covidien : peripheral endovascular interventions (2015) - Medtronic : peripheral endovascular interventions (2015) - Bard : peripheral endovascular interventions (2015) - Spectranetics : peripheral endovascular interventions (2015) - Astra Zeneca : Consultancy (2016) - Medtronic : Consultancy (2016) - Biotronik : Consultancy (2016) - Avinger : Consultancy (2016)

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Task Force



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Brodmann Marianne	<ul style="list-style-type: none"> <li>- Daiichi Sankyo : Speaker Fee (2016)</li> <li>- Bard : Speaker Fee (2016)</li> <li>- Spectranetics : Speaker Fee (2016)</li> <li>- Bayer Healthcare : Speaker Fee (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biotronik : endovascular therapy (2015)</li> </ul>
Cohnert Tina U	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- B.Braun : Vascular Patch/Funding for Dept. Research activities (2015-2016)</li> </ul>
Collet Jean-Philippe	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : apixaban (2015)</li> <li>- Daiichi Sankyo : EDOXABAN (2015)</li> <li>- Bayer : rivaroxaban (2015)</li> <li>- Astra Zeneca : TICAGRELOR (2015)</li> <li>- Eli Lilly : prasugrel (2015-2016)</li> <li>- BMS : apixaban (2016)</li> <li>- Sanofi Aventis : CLOPIDOGREL (2016)</li> <li>- Medtronic : corevalve (2016)</li> <li>- Astra-Zeneca : ticagrelor (2016)</li> <li>- MSD : VORAPAXAR (2016)</li> <li>- Bayer Healthcare : xarelto (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- FEDERATION FRANCAISE DE CARDIOLOGIE : INSTITUTIONAL RESEARCH GRAND (2015)</li> <li>- Bristol Myers Squibb : apixaban (2015-2016)</li> <li>- Medtronic : COREVALVE (2015-2016)</li> </ul>

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Task Force



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<ul style="list-style-type: none"> <li>- Stago : LABORATORY TEST (2016)</li> <li>- Eli Lilly : PRASUGREL (2016)</li> <li>- FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016)</li> <li>- ICAN : THROMBOSIS (2016)</li> <li>- Astra Zeneca : TICAGRELOR (2016)</li> </ul>
Czerny Martin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Vascutek Ltd : FET (2015)</li> <li>- Medtronic : TEVAR (2015-2016)</li> <li>- Bolton Medical : TEVAR (2015-2016)</li> <li>- Vascutek Ltd : Classical surgery (2016)</li> </ul>
De Carlo Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : bioresorbable scaffolds (2015-2016)</li> <li>- Volcano : iFR (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : vorapaxar (2015-2016)</li> <li>- Bayer : rivaroxaban (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- The Medicines Company : bivalirudin (2015)</li> </ul>
Debus Sebastian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medskin Solutions : Collagen Wound Dressings (2015)</li> <li>- Boehringer-Ingelheim : NOAC (2015-2016)</li> <li>- Bayer AG : Rivaroxaban (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Cook Medical : Aortic Stent Grafting (2015-2016)</li> </ul>
Desormais Ileana	<p>Nothing to be declared (2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : ANTITHROMBOTIC (2015)</li> </ul>

# 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Task Force



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Espinola-Klein Christine	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merk Sharp &amp; Dohme : Advisory Board Vorapaxar (2015)</li> <li>- Daiichi Sankyo : Speakers fees (2015)</li> <li>- Pfizer : Speakers fees (2015)</li> <li>- Bristol Myers Squibb : Speakers fees (2015)</li> <li>- Leo Pharma : Speakers fees (2015)</li> <li>- Boehringer Ingelheim : Speakers fees (2015)</li> <li>- Bayer Healthcare : Speakers fees (2015)</li> <li>- Boehringer-Ingelheim : Anticoagulants (2016)</li> <li>- Daiichi Sankyo : Anticoagulants (2016)</li> <li>- Pfizer : Anticoagulants (2016)</li> <li>- Bristol Myers Squibb : Anticoagulants (2016)</li> <li>- Merck Sharp &amp; Dohme : Anticoagulants (2016)</li> <li>- Leo Pharma : Anticoagulants (2016)</li> <li>- Bayer AG : Anticoagulants (2016)</li> <li>- Amgen : Lipid lowering (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Menarini : beta blockers (2016)</li> </ul>
Kahan Thomas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiovascular risk assessment (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Recor Medical : Renal enervation (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : Hypertension (2015)</li> <li>- Pfizer : Lipd lowering (2015)</li> </ul>

# 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Task Force



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Kahan Thomas	<ul style="list-style-type: none"> <li>- Pfizer : Lipid lowering therapy (2016)</li> <li>- Medtronic : Renal denervation (2016)</li> </ul>
Kownator Serge	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulant (2015-2016)</li> <li>- Daiichi Sankyo : anticoagulant (2015-2016)</li> <li>- Bayer Healthcare : anticoagulant (2015-2016)</li> <li>- Astra Zeneca : antiplatelet (2015-2016)</li> <li>- Philips : imaging (2015-2016)</li> <li>- Sanofi Aventis : lipids (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : lipids (2015-2016)</li> <li>- Amgen : lipids (2016)</li> </ul>
Mazzolai Lucia	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : anticoagulants (2015)</li> <li>- Bayer : anticoagulants (2015-2016)</li> <li>- Pfizer : anticoagulants (2015-2016)</li> <li>- Sanofi Aventis : anticoagulants (2015-2016)</li> </ul>
Naylor Ross	Nothing to be declared (2015-2016)
Ricco Jean-Baptiste	Nothing to be declared (2015-2016)
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : coronary catheters (2015-2016)</li> <li>- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015-2016)</li> <li>- Terumo Inc : coronary catheters (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosensors : devices (2015)</li> </ul>

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Task Force



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Roffi Marco	<ul style="list-style-type: none"> <li>- Boston Scientific : devices (2015-2016)</li> <li>- Medtronic : devices (2015-2016)</li> <li>- Biotronik : devices (2015-2016)</li> <li>- Terumo Inc : devices (2015-2016)</li> <li>- Abbott Vascular : devices (2015-2016)</li> </ul>
Rother Joachim	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : thrombocyte aggregation (2015)</li> <li>- Boehringer-Ingelheim : actilyse, pradaxa (2015-2016)</li> <li>- Pfizer : apixaban (2015-2016)</li> <li>- Bristol Myers Squibb : apixaban (2015-2016)</li> <li>- Bayer Healthcare : NOAC (2015-2016)</li> <li>- Astra Zeneca : ticagrelor (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic Foundation : stent, pfo occluder (2015-2016)</li> </ul>
Sprynger Muriel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulants (2015-2016)</li> <li>- Boehringer-Ingelheim : anticoagulants (2015-2016)</li> <li>- Daiichi Sankyo : anticoagulants (2015-2016)</li> <li>- Bristol Myers Squibb : anticoagulants (2015-2016)</li> <li>- Leo Pharma : low molecular heparin (2015-2016)</li> <li>- St Jude Medical : pace-maker (2015-2016)</li> <li>- Pfizer : anticoagulants (2016)</li> <li>- Sanofi Aventis : low molecular heparin (2016)</li> </ul>

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Task Force



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Sprynger Muriel	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : anticoagulants (2016)
Tendera Michal	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : PCSK9 inhibitor (2015) - Bayer : Aspirin, Acarbose (2015-2016) - Servier : Ivabradine (2015-2016) - Janssen-Cilag : Rivaroxaban (2015-2016)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradine (2015-2016) - Janssen-Cilag : Rivaroxaban (2015-2016) - Celyad : Cell product (2016) - Kowa : Pemafibrate (2016)
Tepe Gunnar	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : study support (2015) - Bayer Healthcare : study support (2015) - B.Braun : study support (2015) - 480 Biomedical : study support (2015) - Medtronic : study support and advisory board (2015) - Boston Scientific : Endovascular (2016) - Medtronic : Endovascular (2016) - Biotronik : Endovascular (2016) - Bard : Endovascular (2016) - Veryan : Endovascular (2016) - B.Braun : Endovascular (2016)

# 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Task Force



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Tepe Gunnar	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : DCB (2016)</li> <li>- Biotronik : DCB (2016)</li> <li>- B.Braun : DCB (2016)</li> <li>- Bayer AG : DCB (2016)</li> <li>- Boston Scientific : DCB, DES (2016)</li> <li>- Bard : DCB, Stent (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : DCB (2015)</li> <li>- B.Braun : DCB (2015)</li> <li>- Bayer Healthcare : Drug (2015)</li> <li>- 480 Biomedical : Stent (2015)</li> <li>- Bard : Stent and DCB (2015)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Boston Scientific : DES (2016)</li> </ul>
Venermo Maarit	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Abdominal aortic aneurysm (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Endovascular stents (2015)</li> <li>- Quintiles : Gene study on critical limb ischemia (2015)</li> <li>- Sanofi Aventis : Klexane (2015)</li> <li>- Grex Medical : Biolitec Laser (2015-2016)</li> <li>- Medtronic : Endurant (2015-2016)</li> <li>- Gore : Gore Excluder (2015-2016)</li> <li>- Cook Medical : Zenith (2015-2016)</li> </ul>



# 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Task Force



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Vlachopoulos Charalambos	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : Erectile Dysfunction (2015)</li> <li>- Sanofi Aventis : Hypertension (2015)</li> <li>- Servier : Hypertension-Dyslipidemia (2015)</li> <li>- Menarini : Angina (2015-2016)</li> <li>- Pfizer : Apixaban (2015-2016)</li> <li>- Boehringer-Ingelheim : Dabigatran (2015-2016)</li> <li>- Amgen : Dyslipidemia (2015-2016)</li> <li>- Angelini : Dyslipidemia (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : Ezetimibe (2015-2016)</li> <li>- Novartis : Hypertension (2015-2016)</li> <li>- OMRON Healthcare : Hypertension (2015-2016)</li> <li>- PharmaSwiss : Hypertension (2015-2016)</li> <li>- ELPEN : Hypertension (2015-2016)</li> <li>- Merck Serono : Hypertension-Arrhythmias (2015-2016)</li> <li>- Astra Zeneca : Ticagrelor (2015-2016)</li> <li>- Abbott : Dyslipidemia (2016)</li> <li>- Menarini : Erectile Dysfunction, Coronary Artery Disease (2016)</li> <li>- Servier : Hypertension (2016)</li> <li>- Sanofi Aventis : Hypertension, Dyslipidemia (2016)</li> <li>- Bayer : Rivaroxaban (2016)</li> </ul>

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Agewall Stefan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet treatment (2016)
Agu Obiekezie	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. (2016) - Ethicon Endo Surgery GmbH : No products. Faculty at workshop for managing vascular complications of spine surgery  - Cook Medical : Proctor/Trainer for complex aortic interventions (2016)
Amann-Vesti Beatrice	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Anticoagulant (2016)
Bakken Torbjoern	Nothing to be declared (2016)
Beissel Jean	Nothing to be declared (2016)
Bueno Hector	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Apixaban (2016) - Bristol Myers Squibb : Apixaban (2016) - Bayer : Aspirin, rivaroxaban (2016) - Abbott : BVS (2016) - MEDSCAPE-the heart.org : Inespecific (2016) - Servier : ivabradine (2016) - Novartis : Serelaxin, ACZ885, AHF Academy (2016) - Astra Zeneca : Ticagrelor (2016) - Ferrer Internacional : Trinomia (polypill) (2016)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Ticagrelor (2016)  E - Research funding (personal). - BMS : CV013-011 - STANDUP-AHF trial (2016) - Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016) - Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016)

# 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Bueno Hector	- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016)
Coca Antonio	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Serono : Bisoprolol-Amlodipine (2016) - Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016) - Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016) - Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2016)
de Backer Tine Leonie Marie	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - RIZIV Belgium : hypercholesterolemia; non-vitamin K oral anticoagulants; antihypertensives (2016) - Daiichi Sankyo : olmesartan, edoxaban (2016) - Servier : perindopril; ivabradine; CLARIFY-registry; combination perindopril-amlodipine-atorvastatine (2016)
De Borst Gert J	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Johnson & Johnson : Workshop animal lab (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Dutch Heart Foundation : Advise (2016) C - Receipt of royalties for intellectual property. - Astra Zeneca : Speakers fee (2016)
Delgado Victoria	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott Vascular : Mitraclip (2016) D - Research funding (departmental or institutional). - Boston Scientific : Pacemaker-Heart failure (2016) - Medtronic : Pacemaker-Heart failure (2016) - Biotronik : Pacemaker-Heart Failure (2016) - Edwards Lifesciences : Valvular heart disease (2016)
Dick Florian	Nothing to be declared (2016)
Dilic Mirza	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : Anticoagulants (2016) - Sanofi Aventis : Hyperlipidemia (2016)

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Dzerve Vilnis	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Grindeks : Mildronate (2016)
Erol Cetin	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : Hypertension (2016)
Ferrini Marc	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bristol Myers Squibb : Apixaban (2016) - Daiichi Sankyo : Edoxaban (2016) - Novartis : LCZ (2016) - Bayer : Rivaroxaban, Aspirin (2016) - Astra Zeneca : Ticagrelor (2016)
Fras Zlatko	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : alirocumab (2016) - Boehringer-Ingelheim : empagliflozin (diabetes & CVD) (2016) - Amgen : evolocumab (2016) - Astra Zeneca : ticagrelor (2016) D - Research funding (departmental or institutional). - Duke Clinical Research Institute : alirocumab (2016) E - Research funding (personal). - Duke Clinical Research Institute : alirocumab (2016)
Gudjonsson Thorbjorn	Nothing to be declared (2016)
Haumer Markus	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biotronik : Angioplasty devices (2016) - Bristol Myers Squibb : Apixaban (2016) - Boehringer-Ingelheim : Dabigatran (2016) - Takeda Pharmaceuticals : Diabetes (2016)

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Haumer Markus	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Diabetes (2016)</li> <li>- Astra Zeneca : Ticagrelor (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biotronik : Angioplasty devices (2016)</li> <li>- Abbott Vascular : Angioplasty devices (2016)</li> <li>- Bayer Healthcare : Rivaroxaban (2016)</li> </ul>
Ibrahimi Pranvera	Nothing to be declared (2016)
Isachkin Dzmitry	Nothing to be declared (2016)
Jarai Zoltan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Egis Pharma : antihypertensive agents, cilostazol (2016)</li> <li>- Richter Gedeon Pharmaceuticals : antihypertensive agents, cilostazol (2016)</li> <li>- Krka Pharma : antihypertensive agents, rosuvastatin (2016)</li> <li>- Berlin Chemie AG : antihypertensive therapy, metformin (2016)</li> <li>- Pfizer : apixaban (2016)</li> <li>- Merck Kft : bisoprolol, amlodipine (2016)</li> <li>- Boehringer-Ingelheim : empagliflozin, dabigatran (2016)</li> <li>- Servier : procoralan, antihypertensive agents (2016)</li> <li>- Bayer : rivaroxaban, aspirin (2016)</li> <li>- Astra Zeneca : statin (2016)</li> <li>- Orion : warfarin (2016)</li> </ul>
Jonas Michael	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medinol : peripheral vascular disease (2016)</li> </ul>
Kakkos Stavros	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- vican : elastic stockings (2016)</li> </ul>

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Kakkos Stavros	<ul style="list-style-type: none"> <li>- Leo Pharma : innohep (2016)</li> <li>- Bayer Healthcare : xarelto (2016)</li> </ul>
Karetova Debora	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Zentiva : antihypertensives/statins/vasodilatator (2016)</li> <li>- Astra Zeneca : antiplatelets/ ticagrelor (2016)</li> <li>- Pfizer : apixaban in VTE (2016)</li> <li>- Servier : chronic venous insuff./MPFF (2016)</li> <li>- Boehringer-Ingelheim : dabigatran in VTE (2016)</li> <li>- Bayer AG : rivaroxaban in VTE (2016)</li> <li>- Amgen : treatment of dyslipidaemia/evolocumab (2016)</li> <li>- Alfa-Wassermann : venous thrombembolism (VTE)/sulodexide (2016)</li> </ul>
Katus Hugo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Lixiana_NOAK (2016)</li> <li>- Astra Zeneca : Ticagrelor (2016)</li> <li>- Bayer Vital : Xarelto-NOAK (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : Biobank (2016)</li> <li>- Philips : MRT (2016)</li> </ul>
Knuuti Juhani	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Orion : Brain diseases (2016)</li> <li>- AC Immune : Brain diseases (2016)</li> <li>- Antaros : Endocrinology (2016)</li> <li>- Boehringer-Ingelheim : Neurology (2016)</li> <li>- MSD : Neurology (2016)</li> </ul>

# 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Knuuti Juhani	- GE Gealthcare : Neurology (2016)
Kolh Philippe H	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet agents (2016) - B.Braun : Surgical instruments (2016)
Konradi Alexandra	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : hypertension (2016) - Pfizer : hypertension (2016) - Servier : hypertension (2016) - Berlin Chemie AG : hypertension (2016)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : heart failure (2016) - Berlin Chemie AG : hypertension (2016) - Servier : hypertension, CHF (2016)
Lighezan Daniel Florin	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Terapia : Antiaggregation (2016) - Bayer : Anticoagulation (2016) - Boehringer-Ingelheim : Anticoagulation (2016) - Pfizer and BMS Alliance : Anticoagulation (2016) - Amgen : Dyslipidemia (2016) - Mylan : Hypertension and Dyslipidemia (2016) - Astra Zeneca : Hypertension and Dyslipidemia and Acute Coronary Syndromes (2016) - Novartis : Hypertension and Heart Failure (2016) - Servier : Hypertension and heart Failure (2016) - Labormed : vascular pathology (2016)

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Lindholt Jes	E - Research funding (personal). - Danish Heart Foundation : Randomised screening trial (2016) - Free Danish Reserach Councils : Randomised screening trial (2016)
Lunegova Olga	Nothing to be declared (2016)
Madaric Juraj	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : rivaroxaban (2016) - Astra Zeneca : ticagrelor (2016)
Makinen Kimmo	D - Research funding (departmental or institutional). - Grant from State Research Funding : Gene Therapy studies (2016)
Mattle Heinrich Paul	Nothing to be declared (2016)
Messas Emmanuel	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BMS : ELIQUIS (2016) - Novartis : IMATINIB (2016) - ASTRAZANEKA : TICAGRELOR (2016) - Cardiawave : ULTRASON (2016) - Bayer : XARELTO (2016)  D - Research funding (departmental or institutional). - Astraeneca : ticagrelor (2016) - Bayer : XARELTO (2016)
Misonis Nerijus	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : dyslipidemia treatment (2016) - Medtronic : renal denervation (2016)
Mueller Oliver J	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Anticoagulation (2016) - Daiichi Sankyo : Anticoagulation (2016) - Pfizer : Anticoagulation (2016)



## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Mueller Oliver J	<ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoagulation (2016)</li> <li>- Boehringer Ingelheim : Anticoagulation (2016)</li> <li>- Aspen : Anticoagulation (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Metanomics Health : Heart failure (2016)</li> <li>- Unicure : Heart failure (2016)</li> </ul>
Naka Katerina	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Galenica, Greece : Coronary Artery Disease (Trinipatch TTS), Cardiovascular prevention (Trinomia) (2016)</li> <li>- Merck Sharp &amp; Dohme : Dyslipidaemia (2016)</li> <li>- Elpen, Greece : Dyslipidaemia (2016)</li> <li>- Novartis : Heart Failure (2016)</li> <li>- Boehringer-Ingelheim : Oral anticoagulants (2016)</li> <li>- Actelion : Pulmonary Hypertension (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Unrestricted (2016)</li> <li>- Medtronic : Unrestricted (2016)</li> <li>- Servier : Unrestricted (2016)</li> <li>- St Jude Medical : Unrestricted (2016)</li> <li>- Menarini : Unrestricted (2016)</li> <li>- Elpen, Greece : Unrestricted (2016)</li> <li>- Hospital Line, Greece : Unrestricted (2016)</li> </ul>
Naslund Ulf	Nothing to be declared (2016)
Novo Salvatore	Nothing to be declared (2016)
Paapstel Ants	Nothing to be declared (2016)

# 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Pagava Zurab	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Berlin Chemie AG (Georgia) : Spieker fees (2016) - Servier (Georgia) : Spieker fees (2016) - AstraZeneca (Georgia) : Spieker fees (2016)
Petrov Ivo	Nothing to be declared (2016)
Pieniasek Piotr	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Terumo Inc : Carotid Interventions (2016) - Balton : Carotid Interventions (2016)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Terumo Inc : Carotid Interventions (2016) - Balton : Carotid Interventions (2016)
Piepoli Massimo Francesco	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Committee member, Speaker fee (2016) - Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016) - Amgen : Metabolic, Lipid (2016)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Heart Failure Prevention Initiatives (2016)
Pillaha Elton	Nothing to be declared (2016)
Prescott Eva	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astrazeneca : Microvascular disease (2016)
Scheinert Dierk	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Consultancy (2016) - Medtronic : Consultancy (2016) - Biotronik : Consultancy (2016) - Cook Medical : Consultancy (2016) - Abbott Vascular : Consultancy (2016)

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Scheinert Dierk	<ul style="list-style-type: none"> <li>- Cordis : Consultancy (2016)</li> <li>- Trireme : Consultancy (2016)</li> <li>- CR Bard : Consultancy (2016)</li> <li>- Gardia Medical/Allium : Consultancy (2016)</li> <li>- Upstream Peripheral Technologies : Consultancy (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Honoraria (2016)</li> <li>- Medtronic : Honoraria (2016)</li> <li>- CR Bard : Honoraria (2016)</li> </ul>
Sievert Horst	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> <li>- Boston Scientific : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> <li>- Medtronic : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> <li>- Valtech : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> <li>- Occlutech : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> <li>- CVRx : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> <li>- Coherex : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> <li>- Contego : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> <li>- Lifetech : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> <li>- Trivascular : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> <li>- Veryan : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> <li>- St. Jude Medical : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> <li>- InspireMD : devices for angiologic/cardiac intervention (only study honoraria) (2016)</li> </ul>

# 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Sievert Horst	<ul style="list-style-type: none"> <li>- CIBIEM : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- Cardiac Dimensions : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- Celonova : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- Bioventrix : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- pfm Medical : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- Vascular Dynamics : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- Acoredis : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- Carag : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- Hemoteq : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- Ablative Solutions : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- Ancona Heart : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- CGuard : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- Comed B.V : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> <li>- Maquet Getinge Group : devices for angiologic/cardiology intervention (only study honoraria) (2016)</li> </ul>
Silva Melchor Lorenzo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : ANTIAGGREGATION (2016)</p>
Simpson Iain A	Nothing to be declared (2016)
Soliman Hamdy	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet drug therapy (2016)</p>
Sulzenko Jakub	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : rivaroxaban (2016) - Astra Zeneca : ticagrelor (2016)</p> <p>E - Research funding (personal). - Czech society of cardiology : none (2016)</p>

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Taberkant Mustafa	Nothing to be declared (2016)
Tamargo Juan Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : Angina, diabetes (2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Committee Member (2016) - Ferrer Internacional : Polypill (2016)</p>
Teles Rui	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Cardiovascular (2016) - Medtronic : Cardiovascular (2016) - St Jude Medical : Cardiovascular (2016) - Abbott Vascular : Cardiovascular (2016)</p> <p>C - Receipt of royalties for intellectual property. - Infortucano : Software company (2016)</p> <p>D - Research funding (departmental or institutional). - Edwards Lifesciences : Cardiovascular (2016)</p>
Tokgozoglulale	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : antiplatelet (2016) - Sanofi Aventis : antiplatelet, lipid (2016) - GlaxoSmithKline : antithrombotic (2016) - Abbott : dyslipidemia (2016) - Recordati International : dyslipidemia (2016) - Mylan : dyslipidemia (2016) - Astra Zeneca : dyslipidemia, hypertension, antiplatelet, pulmonary hypertension (2016) - Novartis : heart failure (2016) - Servier : hypertension (2016) - Amgen : lipid (2016)</p>

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Tokgozoglulale	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : lipid (2016)</li> <li>- Aegerion : lipid (2016)</li> <li>- Pfizer : lipids (2016)</li> <li>- Bayer : pulmonary htn (2016)</li> <li>- Actelion : pulmonary hypertension (2016)</li> <li>- Boehringer-Ingelheim : thrombosis (2016)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Teva Pharmaceutical Industries : anti-cancer treatment (2016)</li> <li>- Sanofi Aventis : anticoagulants (2016)</li> <li>- Pfizer : anticoagulants - apixaban (2016)</li> <li>- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2016)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2016)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2016)</li> <li>- MSD : pulmonary hypertension - riociguat (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Actelion : pulmonary hypertension (2016)</li> <li>- Bayer Healthcare : pulmonary hypertension (2016)</li> </ul>
Tosev Slavco	Nothing to be declared (2016)
Tsakountakis Nikolaos	Nothing to be declared (2016)
Tunon Fernandez Jose	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : New lipid lowering drugs PCSK9 inhibitors (2016)</li> </ul>
Vega De Ceniga Melina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Consultancy for EUCLID trial analysis (2016)</li> <li>- European Society for Vascular Surgery : EJVES Associate Editor (2016)</li> </ul>

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Vega De Ceniga Melina	(2016) <ul style="list-style-type: none"> <li>- Aspen Pharma : Teacher in a National residents' course organized by SEACV and partially sponsored by Aspen Pharma</li> <li>- Leo Pharma : Teacher in a National residents' course organized by the SEACV and funded by Leo Pharma (2016)</li> <li>- Servier : Teacher in a National residents' course organized by the SEACV and funded by Servier (2016)</li> </ul>
Vrkic Kirhmajer Majda	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : dabigatran, venous thromboembolism (2016)</li> <li>- Sandoz : peripheral artery disease for general practice (2016)</li> </ul>
Widimsky Petr	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Servier : Antiischemic agents (2016)</li> <li>- Astra Zeneca : Antithrombotic agents (2016)</li> <li>- Bayer : Antithrombotic agents (2016)</li> <li>- Boehringer-Ingelheim : Antithrombotic agents (2016)</li> <li>- Medtronic : Stents (2016)</li> </ul>
Windecker Stephan	D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Boston Scientific : General Cardiology (2016)</li> <li>- St Jude Medical : General Cardiology (2016)</li> <li>- Terumo Inc : General Cardiology (2016)</li> <li>- Bracco Pharmaceutical : General Cardiology (2016)</li> </ul>
Zamorano Gomez Jose Luis	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Philips : 3D Echocardiography. (2016)</li> <li>- Servier : Clinical case presentation during ESC Cong 2016 (2016)</li> <li>- Pfizer : speaker CV risk factors. (2016)</li> <li>- MSD : speaker. CV risk factors (2016)</li> </ul> D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Echo for TAVi assessment &amp; Epidemiology of Ao stenosis (2016)</li> <li>- Abbott : Epidemiology study of Mitral regurgitation (2016)</li> </ul>

## 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) - Reviewers



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Zavatta Marco	Nothing to be declared (2016)
Zelveian Parounak	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Takeda Pharmaceuticals : Hypertension (2016) - Egis Pharma : Hypertension (2016) - Grindex : Hypertension (2016) - Pfizer : Hypertension & Atherosclerosis (2016) - Krka Pharma : Hypertension & Atherosclerosis (2016)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Krka Pharma : Hypertension (2016)



## Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Aboyans Victor	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Hyperlipidemia (2016) - Novartis : Hypertension (2016) - Boehringer-Ingelheim : Oral anticoagulation (2016) - Bayer Healthcare : Oral anticoagulation (2016) - Pfizer/BMS alliance : Oral anticoagulation (2016)
Agewall Stefan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet treatment (2016)
Barbato Emanuele	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Education courses on rotational atherectomy (2016) - St Jude Medical : Educational courses on FFR (2016) D - Research funding (departmental or institutional). - St Jude Medical : Unrestricted grant for an investigator-driven study (2016)
Bueno Hector	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Apixaban (2016) - Bristol Myers Squibb : Apixaban (2016) - Bayer : Aspirin, rivaroxaban (2016) - Abbott : BVS (2016) - MEDSCAPE-the heart.org : Inespecific (2016) - Servier : ivabradine (2016) - Novartis : Serelaxin, ACZ885, AHF Academy (2016) - Astra Zeneca : Ticagrelor (2016) - Ferrer Internacional : Trinomia (polypill) (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Ticagrelor (2016)

## Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Bueno Hector	E - Research funding (personal). <ul style="list-style-type: none"> <li>- BMS : CV013-011 - STANDUP-AHF trial (2016)</li> <li>- Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016)</li> <li>- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 &amp; 2 (2016)</li> <li>- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016)</li> </ul>
Coca Antonio	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Merck Serono : Bisoprolol-Amlodipine (2016)</li> <li>- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016)</li> <li>- Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016)</li> <li>- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2016)</li> </ul>
Collet Jean-Philippe	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- BMS : apixaban (2016)</li> <li>- Sanofi Aventis : CLOPIDOGREL (2016)</li> <li>- Medtronic : corevalve (2016)</li> <li>- Eli Lilly : PRASUGREL (2016)</li> <li>- Astra-Zeneca : ticagrelor (2016)</li> <li>- MSD : VORAPAXAR (2016)</li> <li>- Bayer Healthcare : xarelto (2016)</li> </ul> D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : APIXABAN (2016)</li> <li>- Medtronic : COREVALVE (2016)</li> <li>- Stago : LABORATORY TEST (2016)</li> <li>- Eli Lilly : PRASUGREL (2016)</li> <li>- FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016)</li> </ul>

## Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<ul style="list-style-type: none"> <li>- ICAN : THROMBOSIS (2016)</li> <li>- Astra Zeneca : TICAGRELOR (2016)</li> </ul>
Coman Ioan Mircea	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : anticoagulants (2016)</li> <li>- Johnson &amp; Johnson : antithrombotic (2016)</li> <li>- Bayer AG : antithrombotic (2016)</li> <li>- Sanofi Aventis : dyslipidemia (2016)</li> <li>- Fournier Laboratories : dyslipidemia (2016)</li> <li>- Amgen Inc : dyslipidemia , (2016)</li> <li>- Novartis : HF (2016)</li> <li>- Vifor International : iron deficiency (2016)</li> <li>- Actelion : PHT (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : anticoagulants (2016)</li> <li>- Johnson &amp; Johnson : antithrombotic (2016)</li> <li>- Bayer AG : antithrombotic (2016)</li> <li>- Sanofi Aventis : dyslipidemia (2016)</li> <li>- Amgen Inc : dyslipidemia (2016)</li> <li>- Fournier Laboratories : dyslipidemia (2016)</li> <li>- Novartis : HF (2016)</li> <li>- Vifor International : iron deficiency (2016)</li> <li>- Actelion : PHT (2016)</li> </ul>
Delgado Victoria	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : Mitraclip (2016)</li> </ul>

## Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Delgado Victoria	D - Research funding (departmental or institutional). - Boston Scientific : Pacemaker-Heart failure (2016) - Medtronic : Pacemaker-Heart failure (2016) - Biotronik : Pacemaker-Heart Failure (2016) - Edwards Lifesciences : Valvular heart disease (2016)
Fitzsimons Donna	Nothing to be declared (2016)
Gaemperli Oliver	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE-Healthcare : Imaging (2016) - Amgen Inc : PCSK9 (2016) - Servier : Procorolan (2016)
Hindricks Gerhard	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016) - Biotronik : CIEDs and interventional electrophysiology (2016)  D - Research funding (departmental or institutional). - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016)
lung Bernard	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Edwards Lifesciences : Heart Valve Prostheses (2016)
Juni Peter	Nothing to be declared (2016)
Katus Hugo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : Lixiana_NOAK (2016) - Astra Zeneca : Ticagrelor (2016) - Bayer Vital : Xarelto-NOAK (2016)  D - Research funding (departmental or institutional). - St Jude Medical : Biobank (2016)

## Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Katus Hugo	- Philips : MRT (2016)
Knuuti Juhani	D - Research funding (departmental or institutional). - Orion : Brain diseases (2016) - AC Immune : Brain diseases (2016) - Antaros : Endocrinology (2016) - Boehringer-Ingelheim : Neurology (2016) - MSD : Neurology (2016) - GE Gealthcare : Neurology (2016)
Lancellotti Patrizio	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - St Jude Medical : Echo course (2016) - Servier : Ischemic Heart Disease (2016)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : NOAC (2016) - Medtronic : Structural disease (2016)
Leclercq Christophe	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : devices (2016) - Medtronic : devices (2016) - Sorin Group : devices (2016) - St Jude Medical : devices (2016) - Biotronik : devices (2016) - Bayer Healthcare : DOAC (2016)
McDonagh Theresa	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Vifor International : Ferrinject (2016) - Novartis : Honoraria (2016)
Piepoli Massimo Francesco	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Committee member, Speaker fee (2016)

## Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Piepoli Massimo Francesco	<ul style="list-style-type: none"> <li>- Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016)</li> <li>- Amgen : Metabolic, Lipid (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure Prevention Initiatives (2016)</li> </ul>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulant, diabetes (2016)</li> <li>- Abbott Vascular : devices (2016)</li> <li>- Respicardia : devices (2016)</li> <li>- BioControl : devices (2016)</li> <li>- Novartis : heart failure (2016)</li> <li>- Cardiorentis : heart failure (2016)</li> <li>- Berlin Chemie AG : heart failure (2016)</li> <li>- Bayer Healthcare : heart failure (2016)</li> <li>- Vifor Pharma ltd : heart failure (2016)</li> <li>- CIBIEM : heart failure (2016)</li> <li>- Servier : heart failure, coronary artery disease (2016)</li> <li>- Amgen : heart failure, lipids (2016)</li> <li>- Pfizer : lipids (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Respicardia : anticoagulant (2016)</li> <li>- BioControl : devices (2016)</li> <li>- DC Device : devices (2016)</li> <li>- Novartis : heart failure (2016)</li> <li>- Cardiorentis : heart failure (2016)</li> </ul>

## Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- Bayer Healthcare : heart failure (2016)</li> <li>- CIBIEM : heart failure (2016)</li> <li>- Servier : heart failure, coronary artery disease (2016)</li> <li>- Amgen : heart failure, lipids (2016)</li> </ul>
Richter Dimitrios	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : CAD- hypertension (2016)</li> <li>- Novartis : hypertension (2016)</li> <li>- Abbott : lipids (2016)</li> <li>- Amgen : lipids (2016)</li> <li>- Sanofi Aventis : Lipids (2016)</li> <li>- Lilly : Lipids (2016)</li> <li>- Unilever : lipids (2016)</li> <li>- Merck Sharp &amp; Dohme : lipids (2016)</li> <li>- Angelini : Lipids (2016)</li> <li>- Vianex : lipids (2016)</li> <li>- Galenica : Lipids (2016)</li> <li>- Teva Pharmaceutical Industries : lipids, hypertension (2016)</li> <li>- Swisspharma : lipids-hypertension (2016)</li> <li>- Astra Zeneca : lipids-thrombosis (2016)</li> <li>- Pfizer : lipids-thrombosis (2016)</li> <li>- Winmedica : lipids-thrombosis (2016)</li> <li>- Boehringer-Ingelheim : thrombosis (2016)</li> <li>- Bayer Healthcare : Thrombosis (2016)</li> </ul>

## Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Terumo Inc : coronary catheters (2016)</li> <li>- Johnson &amp; Johnson : coronary catheters (2016)</li> <li>- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boston Scientific : devices (2016)</li> <li>- Medtronic : devices (2016)</li> <li>- Biotronik : devices (2016)</li> <li>- Terumo Inc : devices (2016)</li> <li>- Abbott Vascular : devices (2016)</li> </ul>
Shlyakhto Evgeny	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Krka Pharma : Arterial Hypertension (2016)</li> <li>- Novartis : Arterial Hypertension, Heart Failure (2016)</li> <li>- Merck Sharp &amp; Dohme : Atherosclerosis (2016)</li> <li>- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016)</li> <li>- Pfizer : General Cardiology (2016)</li> </ul>
Simpson Iain A	Nothing to be declared (2016)
Windecker Stephan	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boston Scientific : General Cardiology (2016)</li> <li>- St Jude Medical : General Cardiology (2016)</li> <li>- Terumo Inc : General Cardiology (2016)</li> <li>- Bracco Pharmaceutical : General Cardiology (2016)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Philips : 3D Echocardiography. (2016)</li> <li>- Servier : Clinical case presentation during ESC Cong 2016 (2016)</li> </ul>



## Committee for Practice Guidelines 2016-2018 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<ul style="list-style-type: none"> <li>- Pfizer : speaker CV risk factors. (2016)</li> <li>- MSD : speaker. CV risk factors (2016)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Echo for TAVi assessment &amp; Epidemiology of Ao stenosis (2016)</li> <li>- Abbott : Epidemiology study of Mitral regurgitation (2016)</li> </ul> </li> </ul>